Next Generation Trial Feasibility: Better Planning Through Simulation
Learn how sponsors and CROs are using the new Enforesys^® software to accurately forecast enrollment milestones, identify problem sites early

Wednesday, May 13th, 11:00AM - 12:00noon Eastern US, 16:00 UK, 17:00 EU

Can't attend but interested?   Request the slides and webinar replay

Trial planners are under increasing pressure to ensure their trials are completed on time and on budget. But far too many clinical studies take longer than expected to achieve their enrollment targets, often leading to discontinuations. How can we better predict patient recruitment milestones with sufficient confidence?

Pfizer's Chris Conklin and Charles Liu of Cytel examine the value of using simulation software - Enforesys - to aid prediction and decision-making. Using historical data and other inputs known to affect enrollment, Enforesys allows planners to make accurate, data-driven predictions of enrollment milestones. Competing strategies can be compared directly, and potential challenges flagged early. Finally, the enrollment strategy can be clearly communicated to the rest of the clinical team.

Attend and learn:
- Why trials typically fail to meet forecasted enrollment rates: What are we missing?
- The benefit of expressing enrollment cycle times in probabilistic terms
- How to use Monte Carlo-based simulation to create a more realistic enrollment plan
- Generating and aligning input parameters from stakeholders

The Presenters

Chris Conklin
Director, Pfizer Feasibility Center of Excellence

Charles Liu
Cytel Statistician and Product Mananger

Who should attend

• Biopharma and device R&D leaders determined to start trials on-time, maintine development timelines
• Sponsor company and CRO personnel enegaged in determining trial feasibility
• Program/project managers interested in learning about new predictive tools for site assessment
• Any clinical professional interested in understanding why trials fall short on recruitment goals